Merck & Co. Inc. (MRK) announced that the topline data from the Phase 2b/3 BRUNELLO trial for its investigational drug Remigromig (MK-3000) has met its primary endpoint. The trial is evaluating the drug for the treatment of Diabetic Macular Edema (DME).
Remigromig, previously known by the development code EYE103, is an investigational therapy being developed by the company. The BRUNELLO trial is a pivotal study designed to assess the efficacy and safety of the treatment in patients suffering from DME, a complication of diabetes that can lead to vision loss.
The company stated that the topline data demonstrated that the treatment met its primary endpoint. While the specific details of the results were not fully disclosed in the provided text, the announcement confirms that the data has been generated and analyzed.
